These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 23319802)

  • 1. mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis.
    Zhao L; Yue P; Khuri FR; Sun SY
    Cancer Res; 2013 Mar; 73(6):1946-57. PubMed ID: 23319802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme.
    Panner A; Crane CA; Weng C; Feletti A; Parsa AT; Pieper RO
    Cancer Res; 2009 Oct; 69(20):7911-6. PubMed ID: 19808964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
    Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
    Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589.
    Kauh J; Fan S; Xia M; Yue P; Yang L; Khuri FR; Sun SY
    PLoS One; 2010 Apr; 5(4):e10376. PubMed ID: 20442774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTORC1/2 inhibitor and curcumin induce apoptosis through lysosomal membrane permeabilization-mediated autophagy.
    Seo SU; Woo SM; Lee HS; Kim SH; Min KJ; Kwon TK
    Oncogene; 2018 Sep; 37(38):5205-5220. PubMed ID: 29849119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma.
    Wang Q; Wei F; Li C; Lv G; Wang G; Liu T; Bellail AC; Hao C
    PLoS One; 2013; 8(8):e73175. PubMed ID: 23991179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Cathepsin S Induces Mitochondrial ROS That Sensitizes TRAIL-Mediated Apoptosis Through p53-Mediated Downregulation of Bcl-2 and c-FLIP.
    Seo BR; Min KJ; Woo SM; Choe M; Choi KS; Lee YK; Yoon G; Kwon TK
    Antioxid Redox Signal; 2017 Aug; 27(4):215-233. PubMed ID: 27927016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.
    Zhang T; Wang X; He D; Jin X; Guo P
    Anticancer Drugs; 2014 Sep; 25(8):887-97. PubMed ID: 24714080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells.
    Li S; Oh YT; Yue P; Khuri FR; Sun SY
    Oncogene; 2016 Feb; 35(5):642-50. PubMed ID: 25893295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells.
    Zhao L; Yue P; Lonial S; Khuri FR; Sun SY
    Mol Cancer Ther; 2011 Dec; 10(12):2415-25. PubMed ID: 21914854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel Akt inhibitor API-1 induces c-FLIP degradation and synergizes with TRAIL to augment apoptosis independent of Akt inhibition.
    Li B; Ren H; Yue P; Chen M; Khuri FR; Sun SY
    Cancer Prev Res (Phila); 2012 Apr; 5(4):612-20. PubMed ID: 22345097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
    Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
    Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
    Zeng Z; Shi YX; Tsao T; Qiu Y; Kornblau SM; Baggerly KA; Liu W; Jessen K; Liu Y; Kantarjian H; Rommel C; Fruman DA; Andreeff M; Konopleva M
    Blood; 2012 Sep; 120(13):2679-89. PubMed ID: 22826565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.
    Zhitao J; Long L; Jia L; Yunchao B; Anhua W
    Tumour Biol; 2015 Dec; 36(12):9621-30. PubMed ID: 26142735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitin-specific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme.
    Panner A; Crane CA; Weng C; Feletti A; Fang S; Parsa AT; Pieper RO
    Cancer Res; 2010 Jun; 70(12):5046-53. PubMed ID: 20484045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
    Ravichandran K; Zafar I; Ozkok A; Edelstein CL
    Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
    Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
    J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
    Yao W; Yue P; Khuri FR; Sun SY
    Oncotarget; 2015 Oct; 6(33):34669-79. PubMed ID: 26415225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.